PlainRecalls
LowClass IIITerminated

FDA Drug recall · Reported November 20, 2024

Hydralazine HCl Tablets, USP, 25mg, Rx only, 100 tablets per carton, Distributed by: Avet Pharmaceuticals Inc., East Brunswick, NJ 08816, Distributed by: MAJOR Pharmaceuticals, Livonia, MI, 48152, USA, NDC 0904-6441-61.

Failed Impurities/Degradation Specifications; during routine stability testing for impurities.

Recall #
D-0045-2025
Affected scope
25814 tablets
Initiated
November 5, 2024
Compiled from official public sources by the editorial team.
Verify with FDA Drug →
View my saved recalls

The Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories recalled Hydralazine HCl Tablets, USP, 25mg, Rx only, 100 tablets per carton, Distributed by: Avet… - a low-severity action.

Hydralazine HCl Tablets, USP, 25mg, Rx only, 100 tablets per carton, Distributed by: Avet… was recalled by The Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories in November 20, 2024. Reason: Failed Impurities/Degradation Specifications; during routine stability testing for impurities.. Check the official notice for the remedy. Verify recall #D-0045-2025 with the FDA Drug before acting.

The recall

The Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories issued this low-severity FDA Drug recall-Failed Impurities/Degradation Specifications; during routine stability testing for impurities..

Low
severity level
Class III
classification
November 20, 2024
reported

Sourced from official FDA Drug enforcement records. Verify recall #D-0045-2025 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.

Recall Insight

This FDA Drug action (record #D-0045-2025) was formally reported on November 20, 2024, with the manufacturer initiating the action on November 5, 2024. It is classified under Low severity (Class III), with a current status of Terminated. The Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories is listed as the recalling firm, operating out of La Vergne, TN. Federal records list the affected scope as 25814 tablets.

The documented reason for this recall is: Failed Impurities/Degradation Specifications; during routine stability testing for impurities. Distribution data in the federal record shows the product reached: Nationwide in the US.. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.

Within the same product category the archive holds 6 closely related recalls, 5 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.

Drugs & Medications recalls over time

Where this recall sits in its category - 14,287 drugs & medications recalls on record

-50005001,0001,5002,000 2006201220152018202120242026 263
Severity2487872426High severity (most serious)Moderate severityLow severity
Where this recall sits in the database

Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified low severity.

Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.

Severity

Low

Affected scope

25814 tablets

Related Recalls

6

5 from same agency

Product description

Hydralazine HCl Tablets, USP, 25mg, Rx only, 100 tablets per carton, Distributed by: Avet Pharmaceuticals Inc., East Brunswick, NJ 08816, Distributed by: MAJOR Pharmaceuticals, Livonia, MI, 48152, USA, NDC 0904-6441-61.

Reason for recall

Failed Impurities/Degradation Specifications; during routine stability testing for impurities.

Recall Profile

Structured summary of the FDA Drug recall record
Attribute Value
Agency U.S. Food and Drug Administration
Severity class Low (Class III)
Status Terminated
Recall number D-0045-2025
Date reported November 20, 2024
Date initiated November 5, 2024
Recalling firm The Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories
Firm location La Vergne, TN
Affected scope 25814 tablets
Distribution Nationwide in the US.

Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.

What to do with this recall

Match your product against the recall record, then act on the agency remedy.

  • Check the recall number (D-0045-2025) and product description against the item you own. Search the archive
  • Confirm the current status with FDA Drug before acting, recall details can be updated.
  • Follow the documented remedy (refund, replacement, repair, or disposal) rather than general advice. What to do next

This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.

Frequently Asked Questions

What product was recalled?
Hydralazine HCl Tablets, USP, 25mg, Rx only, 100 tablets per carton, Distributed by: Avet Pharmaceuticals Inc., East Brunswick, NJ 08816, Distributed by: MAJOR Pharmaceuticals, Livonia, MI, 48152, USA, NDC 0904-6441-61.. Recalled by The Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories. Units affected: 25814 tablets.
Why was this product recalled?
Failed Impurities/Degradation Specifications; during routine stability testing for impurities.
Which agency issued this recall?
This recall was issued by the FDA Drug on November 20, 2024. Severity: Low. Recall number: D-0045-2025.
Where was the recalled product distributed?
Distribution: Nationwide in the US..
How do I check if my product is affected by a recall?
Check the product description and recall number (D-0045-2025) against your product. Visit the official FDA Drug website for the most current information. You can also use our Recall Checker tool to search by product name or brand.
Should I stop using a recalled medication or medical device?
Do not stop using a recalled medication or device without consulting your healthcare provider first, as abruptly discontinuing treatment could pose its own health risks. Your doctor can advise on alternatives or whether the recall applies to your specific product lot. Check the recall number and lot information against your product packaging.

Nearby Recalls in This Category

Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.

Compare this recall with PRED MILD, prednisolone acetate ophthalmic suspension, USP,… →

Browse all Drugs & Medications recalls →

Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported November 20, 2024. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.